Eligible nominees include individuals, teams of researchers, or research institutions and are nominated solely for the scientific merit of their work. Although preference is given to scientific breakthroughs with direct or obvious clinical applications, all major accomplishments in type 1 or type 2 research are considered by the Selection Jury. Employees of for-profit pharmaceutical or biotechnology companies are not eligible.
Nominations for the Prize are made by members of the Selection Jury and are therefore not open to application. However, Letters of Recommendation for nominations will be accepted to afford the community at large an opportunity to suggest Nominees for the Prize to the Selection Jury.
Letters of Recommendation for nominations are provided to the jurors for consideration. Jurors may review these Letters at their discretion. Any person writing a Letter of Recommendation for Nomination is requested not to make direct contact with Jurors for the purpose of soliciting a recommendation for nominations or selection. Letters must not exceed 1,000 words. Letters are confidential and only made available to members of the Selection Jury.
View key dates and deadlines for the open call for nominations.
Selection Jury members are appointed by Harold Hamm Diabetes Center representatives with priority given to individuals who have served in international capacities in the field of diabetes research such as editors of major diabetes journals or recent leaders of major diabetes-related organizations.
Jed Friedman, PhD, Selection Jury Chairperson
Steven E. Kahn, MB, ChB
Jeffrey Pessin, PhD
Maike Sander, MD
Randy Seeley, PhD
Clay Semenkovich, MD
The University of Oklahoma College of Medicine is recruiting participants for a study aimed at understanding the factors behind Type 2 diabetes in ...
Spring 2024 Newsletter (pdf) The Spring issue highlights: The U54 CIRCLE center grant of $10.5 Million, awarded by NIH Dr. Busik – feature of the ...
A new treatment targeting the root cause of Type 1 diabetes is now available at OU Health, and for pediatric patients at high risk, this new ...